Business Wire

THALES

17.6.2024 09:01:34 CEST | Business Wire | Press release

Share
Thales and CEA Partner on Trusted Generative AI for Defence and Security

To create trusted generative AI solutions, Thales’s cortAIx Lab, the most powerful integrated laboratory for critical AI in Europe, and the CEA, which is one of the world’s most innovative research organisations and is listed alongside Thales in the Clarivate Analytics Top 100 Global Innovators,1 have joined forces to focus on a range of generative AI use cases, in particular for intelligence and command applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240617313286/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alexandre Bounouh, Director of the CEA-List Institute, specialising in smart digital systems, and Bertrand Tavernier, CTO for Thales’s Secure Communications and Information Systems business, at the signing of the partnership agreement on 30 April 2024 in Palaiseau, France. (Photo: Thales)

Bertrand Tavernier, Chief Technical Officer for Thales’s Secure Communications and Information Systems business: This partnership with the CEA’s AI teams will combine the power of their research with our work at cortAIx, Thales’s AI accelerator, which brings together the Group’s technological expertise and deep knowledge of the defence and security sectors. Our customers — governments, armed forces, critical infrastructure operators — need trusted, sovereign generative AI solutions for their critical missions.

Alexandre Bounouh, Director of the CEA’s List Institute, specialising in smart digital systems: This partnership builds on the long-standing collaboration between the CEA and Thales and extends it to the sensitive issue of generative AI, combining the expertise and excellence of the CEA’s research teams in AI safety and security with cortAIx’s strengths in the strategic domain of defence and security. It will support the CEA’s mission in safety, security and artificial intelligence with our partners and all institutional and industry stakeholders in this field.

Use cases for the armed forces

Generative AI can be developed to accelerate OODA command loops (observe, orient, decide, act) and implemented across the entire critical decision chain: sensing and data gathering, data transmission and storage, data processing and decision support.

Generative AI will serve as a trusted smart assistant for users, enabling them to dialogue easily and efficiently with complex systems with the aim of facilitating and accelerating human decision-making and the tempo of operations. For intelligence gathering, for example, multimodal generative AI will make it possible to simultaneously extract, process, correlate and interpret different types of information from multiple sources — such as the web, social media and sensors in a theatre of operations — to generate summaries and accelerate the production of reliable reports.

Thales’s cortAIx Lab and the CEA will also focus on interoperability within coalitions. To simplify communication between member states in the context of a joint operation, trusted generative AI will facilitate interaction between operators and complex systems by translating their intentions into a sequence of actions and translating technical terms into the languages of the various nations involved.

Thales, a leader in trusted AI for mission-critical systems

Thales is a major player in trusted, cybersafe, transparent, explainable and ethical AI for armed forces, aircraft manufacturers and critical infrastructure operators. In 2023, the Group was Europe’s top patent applicant in the field of AI for mission-critical systems. It has more than 600 AI experts and hosts around 100 PhD students every year in AI at cortAIx, Thales’s AI accelerator in the field of research (cortAIx Lab), systems (cortAIx Factory for decision support systems) and sensors (cortAIx Sensors for sonar, radar, radio and optronics). Thanks to cortAIx and its network of world-class industry, start-up and academic partners, Thales is building AI into more than 100 of its products and services. Benefiting from the most advanced sensor and system technologies, these AI capabilities cover the full spectrum of needs in defence, aviation, space, cybersecurity and digital identity. Trusted AI is designed to meet the specific security and sovereignty needs of Thales’s customers. It brings greater efficiency to data analysis and decision support and speeds up the detection, identification and classification of objects of interest and target scenes, while taking account of specific constraints such as cybersecurity, embeddability and frugality in critical environments.

CEA, a key player in trusted AI for mission-critical systems

In the field of artificial intelligence, the CEA is uniquely positioned across the entire AI value chain, with skills ranging from algorithms and software development tools to computing architectures and microelectronics. The hardware and software solutions developed by the CEA with its academic and industry partners are aimed at applications where AI quality and performance are critical. They include sovereign applications for which the CEA is its own customer (cybersecurity, defence, energy) and industrial applications to which the CEA contributes its expertise.

The CEA has developed high-level expertise in AI technologies, enabling the agency to support its industry partners in the development of innovative solutions. At its CEA-List Institute specialising in smart digital systems, the CEA focuses its research on the development of high-performance, trusted and sovereign models.

Working with Thales, the CEA teams will be applying their expertise more specifically to develop LLMs (large language models) and VLMs (vision language models) for the sectors and use cases targeted by Thales.

About Thales 

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity. 

It develops products and solutions that help make the world safer, greener and more inclusive. 

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G. 

Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

About CEA
The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security. As the world’s leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry.
Find out more: www.cea.fr

PLEASE VISIT

Thales Group
Security
Thales
@Thalesgroup

___________________________
1 The CEA is listed with Thales in the Top 100 Global Innovators published by Clarivate Analytics: Thales listed among world’s top 100 most innovative companies for 11 time | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240617313286/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye